Bausch & Lomb Incorporated — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Bausch & Lomb Incorporated appears in 20 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials20

Recruiting shown1

Roles2

SourceClinicalTrials.gov

Clinical trials

20 shown

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular HypertensionNCT07168902 · lead sponsor · 2025-10-24

A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular HypertensionNCT04140279 · lead sponsor · 2022-05-13

Safety and IOP-Lowering Effects of WB007NCT04149899 · lead sponsor · 2019-11-14

Therapeutic Equivalence Study of Generic Brinzolamide vs AzoptNCT03896633 · lead sponsor · 2018-02-28

Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHTNCT01895972 · lead sponsor · 2013-07-05

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular HypertensionNCT01749904 · lead sponsor · 2013-01-31

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular HypertensionNCT01749930 · lead sponsor · 2013-01-01

BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular HypertensionNCT01707381 · lead sponsor · 2012-11-01

Therapeutic Equivalence Study of Generic Brinzolamide vs AzoptNCT01722604 · lead sponsor · 2012-01-01

Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular HypertensionNCT01223378 · lead sponsor · 2010-12-13

A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.NCT00595101 · lead sponsor · 2007-12-01

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for GlaucomaNCT00441883 · lead sponsor · 2007-03-01

Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous DetachmentNCT00198471 · lead sponsor · 2005-07-01

Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous HemorrhageNCT00198497 · lead sponsor · 1999-06-01

Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous HemorrhageNCT00198510 · lead sponsor · 1998-11-01

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical MedicationsNCT04354545 · collaborator · 2021-04-01

Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour PeriodNCT07090044 · collaborator · 2021-08-20

Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual AcuityNCT03931317 · collaborator · 2018-12-03

Evaluation of Ocular Surface Inflammatory Mediators Effected by LotemaxNCT02322528 · collaborator · 2014-04-01

Clinical Trial on Alpha Lipoic Acid in Diabetic Macular EdemaNCT01208948 · collaborator · 2000-07-01

Sponsor roles

lead sponsor15

collaborator5

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.